font size
Sign inprintPrint
CAPITAL MARKETS

Investors Weigh Biotech Results

Podcast: July 26, 2010

The Burrill Report (July 26, 2010): Investors Weigh Biotech Results (.MP3,10.45 Mb)
Earnings season is well underway with Gilead, Genzyme, Biogen Idec, and Roche all having reported their second quarter results. The numbers have been a mixed bag and there are some big questions overhanging key players in the industry. Some investors are looking beyond the quarter, but what they see isn’t always encouraging. We spoke to Adam Feuerstein, senior columnist for The Street.com, about how the second quarter numbers are shaping up, what red flags may be out there, and how investors are looking at the results these days.

[Please login to post comments]

Other recent stories